Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
78 results about "Muscarinic agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A muscarinic agonist is an agent that activates the activity of the muscarinic acetylcholine receptor. The muscarinic receptor has different subtypes, labelled M1-M5, allowing for further differentiation.
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS6517864B1Achieve effectClinical efficacyOrganic active ingredientsAerosol deliveryMuscarinic antagonistMetabolite
Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).
Owner:MCNEIL AB +1
Benzimidazolidinone derivatives as muscarinic agents
InactiveUS6951849B2Inhibition formationInhibit progressBiocideNervous disorderMuscarinic antagonistReceptor subtype
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and / or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Owner:ACADIA PHARMA INC
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/c39d20f2-03bd-480c-bd6a-a01e1d9720ef/US20050192268A1-20050901-C00001.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/c39d20f2-03bd-480c-bd6a-a01e1d9720ef/US20050192268A1-20050901-C00002.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/c39d20f2-03bd-480c-bd6a-a01e1d9720ef/US20050192268A1-20050901-C00003.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
Owner:ACADIA PHARMA INC
Benzimidazolidinone derivatives as muscarinic agents
InactiveUS7087593B2Increase acetylcholine signaling and effectHigh selectivityBiocideSenses disorderReceptor subtypeMuscarinic Agents
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and / or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Owner:ACADIA PHARMA INC
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS20030124179A1Clinical efficacyReduce riskBiocideOrganic active ingredientsMuscarinic antagonistNasal cavity
The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and / or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and / or other transmucosal administration, in order to achieve an effect against overactive bladder and / or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.
Owner:MCNEIL AB
Tetrahydroquinoline analogues as muscarinic agonists
InactiveUS20050209226A1Increased intraocular pressureSenses disorderNervous disorderTreatment useMuscarinics
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Owner:ACADIA PHARMA INC
Muscarinic receptor agonists
InactiveUS6911477B2Increase neurotransmissionSimple processBiocideOrganic chemistryDiseaseMuscarinic agonist
This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of which is mediated by muscarinic receptor agonism.
Owner:PFIZER INC
Muscarinic agonists
Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Owner:ACADIA PHARMA INC
Methods of improving quality of sleep
InactiveUS20110245294A1Improve sleep qualityBiocideNervous disorderAnticholinergic agentsOveractive bladder
Disclosed herein are methods of treating a patient suffering from overactive bladder (OAB) comprising administering to the patient a combination of antimuscarinic or anticholinergic agent and muscarinic agonist for the treatment of poor quality of sleep in the OAB patient.
Owner:THERAVIDA INC
Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
InactiveUS20070053964A1Promote secretionSustained effectOrganic active ingredientsBiocideEyelidSide effect
A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically effective concentration of a muscarinic receptor agonist for promoting lacrimal fluid secretion, which is associated with fewer side effects such as miosis, and a method of promoting lacrimal fluid secretion by administering a percutaneous absorption type ophthalmic preparation containing a muscarinic receptor agonist to the skin surface of the eyelid.
Owner:SENJU PHARMA CO LTD
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/47854f59-05d8-419f-8cc7-8fcf2ee494c1/US20060194784A1-20060831-C00001.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/47854f59-05d8-419f-8cc7-8fcf2ee494c1/US20060194784A1-20060831-C00002.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/47854f59-05d8-419f-8cc7-8fcf2ee494c1/US20060194784A1-20060831-C00003.png "Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
Owner:ACADIA PHARMA INC
Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
Compounds are described that are prodrugs to active compounds that modulate a muscarinic receptor. In some cases, the compounds are prodrugs to N-desmethylclozapine. The compounds may be used to treat neuropsychiatric disorders.
Owner:ACADIA PHARMA INC
Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.
![Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0ab87a8e-7835-451b-8770-82c470c97c6a/US20060199798A1-20060907-C00001.png "Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0ab87a8e-7835-451b-8770-82c470c97c6a/US20060199798A1-20060907-C00002.png "Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
![Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0ab87a8e-7835-451b-8770-82c470c97c6a/US20060199798A1-20060907-C00003.png "Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders")
Owner:ACADIA PHARMA INC
Muscarinic agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a)or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Muscarinic receptor agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2 R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Benzimidazolidinone derivatives as muscarinic agents
InactiveUS20060205785A1Increase acetylcholine signaling and effectHigh selectivityBiocideSenses disorderReceptor subtypeMuscarinic Agents
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and / or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Owner:ACADIA PHARMA INC
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC
Compounds with activity on muscarinic receptors
Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
Owner:BRANN MARK +6
Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent
The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS / BPH) with a substantial storage component is provided.
Owner:ASTELLAS IRELAND
Muscarinic agonists
Owner:ACADIA PHARMA INC
Benzimidazolidinone derivatives as muscarinic agents
InactiveUS20060025402A1Increase acetylcholine signaling and effectHigh selectivityBiocideNervous disorderReceptor subtypeMuscarinic Agents
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and / or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Owner:ACADIA PHARMA INC
Compositions and methods for the treatment of presbyopia
ActiveUS9968594B2Organic active ingredientsPharmaceutical delivery mechanismPhysiologyCycloplegic agent
The invention provides compositions and methods for the treatment of presbyopia. In a preferred embodiment correction of presbyopia occurs without reduction in distance vision acuity. The compositions of the invention preferably contain a muscarinic agonist and a cycloplegic agent.
Owner:LENZ THERAPEUTICS INC
Pharmaceutical compounds
This invention relates to compounds that are agonists of the muscarinic M1 and / or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formulawhere X1; X2; R1 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
ActiveUS20150366855A1Reduce partial pressureStart fastPowder deliveryBiocideDiseaseMuscarinic antagonist
The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Muscarinic agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2′, R2″, R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Methods and compositions for treating hyperhidrosis
ActiveUS10328057B2Speed up heat lossHyperhidrosis is substantially reducedOrganic active ingredientsNervous disorderMuscarinic antagonistSide effect
Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.
Owner:THERAVIDA INC
Muscarinic Agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a)or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Pharmaceutical compounds
This invention relates to compounds that are agonists of the muscarinic M1 and / or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formulawhere Y, R1, R2 and R4 are as defined herein.
Owner:APTALIS PHARMA +1
Muscarinic agonists
ActiveUS20180228791A1High selectivityOrganic active ingredientsNervous disorderMuscarinicsMuscarinic agonist
This invention relates to compounds that are agonists of the muscarinic M4 receptor and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R1, R2, R3, R9 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Muscarinic receptor agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2 R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com